ArticleInfection2016
Polymicrobial pulmonary infection in patients with hematological malignancies: prevalence, co-pathogens, course and outcome.
Article in Infection, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- A systematic review and metanalysis of diagnostic yield of BAL for detection of SARS-CoV-2.Heart & lung : the journal of critical carePooled it
- Respiratory and blood samples metagenomic sequencing in diagnosing pulmonary infections in hematologic patients.BMC infectious diseases · 2026Article
- Clinical pathogen profiles and lung microbiome features in lung infection patients and concurrent cancer: insights from metagenomics next-generation sequencing.Open life sciences · 2026Article
- In-Hospital Mortality Among Hematological Malignancy Patients Undergoing Bronchoscopy for Suspected Invasive Pulmonary Aspergillosis: Focusing on Coinfections and Nodules on Chest CT.Mycopathologia · 2025Article
- China Expert consensus on the application of metagenomic next-generation sequencing for the etiological diagnosis of infections in hematological disorders (2024).Blood science (Baltimore, Md.) · 2025Article
- Evaluation of the efficacy of sulbactam combination therapy for monomicrobial and polymicrobial pulmonary infections caused by multidrug-resistantMicrobiology spectrum · 2025Article
- The Role of Bronchoalveolar Lavage in Therapeutic Antimicrobial Choices for Hematologic Patients with Pulmonary Infiltrates.Medicina (Kaunas, Lithuania) · 2025Observational
- Utilizing Targeted Next-Generation Sequencing for Rapid, Accurate, and Cost-Effective Pathogen Detection in Lower Respiratory Tract Infections.Infection and drug resistance · 2025Article
- Comparative Evaluation of mNGS and Traditional Culture Methods in Pathogen Detection for Pulmonary Infections.Infection and drug resistance · 2025Article
- Comparing the diagnostic value of targeted with metagenomic next-generation sequencing in immunocompromised patients with lower respiratory tract infection.Annals of clinical microbiology and antimicrobials · 2024Article
- Microbiological risk factors, ICU survival, and 1-year survival in hematological patients with pneumonia requiring invasive mechanical ventilation.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024Article
- Exploring the Application of Metagenomic Next-Generation Sequencing in the Diagnosis of Unexplained Pulmonary Infection.International journal of general medicine · 2024Article
- The Differential Diagnostic Value of Chest Computed Tomography for the Identification of Pathogens Causing Pulmonary Infections in Patients with Hematological Malignancies.Infection and drug resistance · 2024Article
- Clinical Features and Outcomes of VAP Due to Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2023Article
- Clinical Evaluation of Metagenomic Next-Generation Sequencing Method for the Diagnosis of Suspected Ascitic Infection in Patients with Liver Cirrhosis in a Clinical Laboratory.Microbiology spectrum · 2023Article
- Invasive Pulmonary Aspergillosis.Journal of fungi (Basel, Switzerland) · 2023Review
- Clinical application value of metagenomic second-generation sequencing technology in hematologic diseases with and without transplantation.Frontiers in cellular and infection microbiology · 2023Article
- Impact of Infection Patterns on the Outcomes of Patients with Hematological Malignancies in Southwest China: A 10-Year Retrospective Case-Control Study.Infection and drug resistance · 2023Article
- Distribution Patterns of Pathogens Causing Lower Respiratory Tract Infection Based on Metagenomic Next-Generation Sequencing.Infection and drug resistance · 2023Article
- When Viruses Meet Fungi: Tackling the Enemies in Hematology.Journal of fungi (Basel, Switzerland) · 2022Review
Corrections and comments
- Commented on by
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe frequency and clinical significance of polymicrobial pneumonia in patients with hematological malignancies (HM) are poorly understood. The aim of the present study is to describe the prevalence, risk factors, clinical characteristics, and outcome of patients with HM and polymicrobial pneumonia.
methodsOver a 5 year period, 436 consecutive adult patients with HM and pulmonary infiltrates underwent diagnostic fiberoptic bronchoscopy with bronchoalveolar lavage. For 219 patients an infectious etiology was diagnosed, of them 45 (20.5 %) had polymicrobial etiology. Risk factors, clinical course and outcome of polymicrobial pulmonary infection in patients with HM were established.
results45 patients with HM were identified with polymicrobial pulmonary infection, 39 of them with two pathogens, and 6 with three. The most common co-pathogen identified was Aspergillus sp. (87 %). Allogeneic hematopoietic stem cell transplantation (HSCT) and graft versus host disease (GVHD) were predictors of polymicrobial infection. Compared to patients with monomicrobial pneumonia, patients with polymicrobialpulmonary infection had a more severe clinical course with more dyspnea (69 vs. 49 %, P = 0.016), hemoptysis (16 vs. 7 %, P = 0.065) and more required respiratory support (27 vs. 17 %, P = 0.125). In-hospital mortality was significantly higher in patients with polymicrobial pulmonary infection than in patients with monomicrobial pulmonary infection (49 vs. 19 %, P < 0.001).
conclusionsPolymicrobial pulmonary infection occurs quite frequently in patients with HM, especially in allogeneic HSCT recipients and in patients with GVHD. The clinical course of polymicrobial pulmonary infection is severe and mortality approaches 50 %. The clinician taking care of these patients should always look for additional copathogens in profoundly immunosuppressed patients with pneumonia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.